Spexis AG
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (NCT03786094) | Spexis AG | 2019-05-30 |
Track Spexis AG automatically
Every clearance here is in the API, with alerts when new ones post.